Stocks · News reference

HSBC Maintains Buy on AbbVie, Raises Price Target to $315

Sep 10, 2026, 2:10 PMBenzinga Newsdesk

HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 11, 2026, 7:24 AMRadhika Anilkumar Nadig
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
AAPL ABBV AMZN BTI CVS
The Motley FoolSep 10, 2026, 8:08 PMRobert Izquierdo
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.
VHT XPH LLY JNJ ABBV
BenzingaSep 10, 2026, 4:41 PMVandana Singh
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.
ABBV